Abstract | BACKGROUND: METHODS: The study enrolled 313 high-risk patients with anterior AMI and LV ejection fraction of <45%, randomly assigned to treatment with carvedilol or metoprolol. Patients were followed-up for a mean period of 13.4 months. The primary end point was time to composite adverse events (t-CAE). The secondary end points were time to composite hard events (t-CHE) and health-related quality of life. RESULTS: No differences were found either in the primary end point of t-CAE or in the secondary end point of t-CHE. A significant benefit was observed in 4 of 8 health-related quality of life domains in the carvedilol group, with fewer carvedilol group patients being withdrawn from therapy in the hospital. CONCLUSIONS: Treatment with carvedilol, in comparison to that with metoprolol in patients with AMI and LV dysfunction, did not differ significantly in regard to the primary end point of t-CAE or to the secondary end point of t-CHE but resulted in better long-term quality of life and favorable early safety profile.
|
Authors | Igor Bogdan Mrdovic, Lidija Zlatimir Savic, Jovan Petar Perunicic, Milika Risto Asanin, Ratko Milorad Lasica, Marinkovic Milutin Jelena, Mihailo Dragomir Matic, Zorana Mihailo Vasiljevic, Miodrag Caslav Ostojic |
Journal | American heart journal
(Am Heart J)
Vol. 154
Issue 1
Pg. 116-22
(Jul 2007)
ISSN: 1097-6744 [Electronic] United States |
PMID | 17584563
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Carbazoles
- Propanolamines
- Carvedilol
- Metoprolol
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Carbazoles
(therapeutic use)
- Carvedilol
- Cause of Death
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Male
- Metoprolol
(therapeutic use)
- Middle Aged
- Myocardial Infarction
(complications, mortality)
- Propanolamines
(therapeutic use)
- Quality of Life
- Survival Rate
- Ventricular Dysfunction, Left
(drug therapy, etiology)
|